Loading...
Loading...
IMV| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 10.2M |
| Operating I/L | -10.2M |
| Other Income/Expense | -0.3M |
| Interest Income | 0.0M |
| Pretax | -10.5M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | -10.8M |
IMV Inc. is a clinical-stage immuno-oncology company specializing in developing therapies for solid and hematological cancers. The company's portfolio is based on its DPX immune-educating technology platform, with lead drug candidate maveropepimut-S in Phase II clinical trials for various cancers, including diffuse large B cell lymphoma, ovarian cancer, and bladder, liver, and microsatellite instability high tumors. Additionally, IMV Inc. is developing DPX-SurMAGE for bladder cancer and DPX-COVID-19 and DPX-RSV for infectious diseases.
